ASX growth shares building base to surge higher

The presence of industry tailwinds and a wave of new catalysts suggest that the following ASX growth stocks could be building a base for a major jump soon.

Weebit Nano Limited (ASX: WBT) 

had an excellent start to FY26 as the company completed the tape-out of its first embedded ReRAM module at onsemi’s 300mm production fab which marks a major step toward integrating Weebit ReRAM into future high-temperature automotive and industrial chips.

It reached its goal of three product-company agreements for 2025 as US customers began integrating its non-volatile memory IP into security and smart battery management solutions.
Financial performance reflected this progress as customer receipts reached a record $7.3 million for the quarter and the company finished the period with a strong balance sheet holding $91.6 million cash.

Weebit Nano’s growth outlook is highly positive as it moves toward ReRAM qualification at DB HiTek, expands test-chip validation at onsemi and advances new licensing agreements with major semiconductor companies.

Megaport Limited (ASX: MP1) 

had one of its strongest years to date as FY25 marked a clear return to growth as Annual Recurring Revenue rose to $243.8 million which is a 20% increase.
The company added 115 new data centres and crossed a major milestone of more than 1,000 connected data centers worldwide which came from strong adoption of new services.

EBITDA reached $62.3 million which is up from $57.1 million last year, gross profit increased to $162 million and cash at bank ended at $102.1 million which is up 41% from FY24.
Megaport’s outlook is growth-focused with FY26 revenue guided to $260–270 million which represents 15–19% year-on-year growth.

Telix Pharmaceuticals Limited (ASX: TLX)

on December 8 said that the first patient was dosed in Part 2 of its ProstACT Global Phase 3 trial for TLX591 which is its lead radiopharmaceutical therapy for metastatic castration-resistant prostate cancer.
For Q3 2025, group revenue reached US$206 million which is up 53% year-on-year and was supported by solid sales of Illuccix and Gozellix.

FY25 revenue guidance was moved higher to US$800–820 million which reflects strong global demand and the company also secured full U.S. reimbursement for Gozellix under HCPCS Level II and TPT status from October 1, 2025 which improves accessibility and supports further growth in North America.
Telix is entering FY26 with favourable conditions in place as expanding global reimbursement, several late-stage clinical trials and rising adoption of its PSMA imaging products provide strong momentum.

NRW Holdings Limited (ASX: NWH) 

has delivered another year of growth in FY25 as revenue rose 12.2% to $3.27 billion which came mainly from strong performance across its Civil and Mining divisions.
The acquisition of Fredon Industries in October 2025 added another business pillar that includes electrical, mechanical, infrastructure, technology and maintenance services.

Financial performance was good even with disruptions from heavy rainfall in Queensland as underlying EBITDA increased 16.8% to $391 million.

The company is in a good spot currently and Fredon gives exposure to long-term trends such as energy transition, digital infrastructure and electrification across Australia and New Zealand.

(Source: Company Reports)